Table 1

Age, FEV₁, peak flow, methacholine PD₂₀, symptom score, and β agonist use in 31 asthmatic subjects at baseline and week 4

	Fluticasone propionate
	Baseline	Week 4	Change (95% CI)	Baseline	Week 4	Change (95% CI)
Mean (SD) age (years)	43 (8)			42 (8)
Mean (SD) FEV₁ (l)	1.86 (0.71)	2.17 (0.78)	0.31 (0.08 to 0.53)^1-150	2.12 (0.67)	2.27 (0.59)	0.15 (–0.08 to 0.3)
Geometric mean (log SD) PD₂₀ (μmol)^1-152	0.32 (0.2)	0.81 (0.2)	1.9 DD^1-151	0.36 (0.2)	0.51(0.2)	0.5 DD^1-151
Mean (SD) morning PEF (l/min)	317 (105)	358 (107)	41 (–3 to 85)	348 (92)	376 (89)	28 (11 to 45)^1-150
Mean (SD) evening PEF (l/min)	332 (100)	359 (93)	27 (6 to 48)^1-150	357 (89)	375 (89)	18 (–5 to 43)
Median (range) daily symptom score	2.25 (1 to 4)	1 (0 to 4)	–1.25	2 (1 to 6)	1 (0 to 4)	–1^1-150
Median (range) daily β agonist use (puffs/day)	6 (2.5 to 12)	4 (0 to 10)	–2^1-150	5 (2 to 12)	2 (0 to 14)	–3^1-150

FEV₁ = forced expiratory volume in one second; PEF = peak expiratory flow; DD = doubling doses.
↵1-150 p<0.05 between baseline and week 4.
↵1-151 p<0.05 between fluticasone propionate and budesonide.
↵1-152 PD₂₀ methacholine was only performed in 10 subjects in each group.